Tenon Medical, Inc. (TNON) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite some positive developments like the SiVantage acquisition and the upcoming Symmetry Plus launch, the company's financial performance shows significant declines in revenue, gross profit, and net loss compared to the previous year. Additionally, management's vague responses about the merger's financial impact and the uncertain timeline for Symmetry Plus launch contribute to negative sentiment. The economic uncertainty and market adoption risks further add to the concerns. The lack of strong guidance or shareholder return plans also supports a negative outlook for the stock price in the short term.
Key Financial Performance
Revenue for Q2 2025 $564,000 compared to $901,000 in the same period last year, a decline primarily due to lower procedure volumes and account mix headwinds driven by the strategic shift in commercial initiatives with the impending SiVantage acquisition.
Revenue for the 6 months ended June 30, 2025 $1.3 million compared to $1.6 million in the same period in 2024, a decline due to the same reasons as the quarterly revenue drop.
Gross profit for Q2 2025 $245,000 or 43% of revenue compared to $470,000 or 52% of revenue in the prior year quarter, a decline due to reduced procedure volumes and lower revenue with consistent variable direct product costs and relative fixed production overhead costs year-over-year.
Gross profit for the 6 months ended June 30, 2025 $568,000 or 44% of revenue compared to $940,000 or 58% of revenue in the prior year period, with the decline attributed to the same reasons as the quarterly gross profit drop.
Operating expenses for Q2 2025 $3.1 million, down from $4.3 million in the prior year period, a 29% reduction driven by lower expenses across G&A, R&D, and sales and marketing, as well as disciplined spending, project timing, and reduced stock-based compensation.
Operating expenses for the 6 months ended June 30, 2025 $7.1 million compared to $8.3 million in the prior year period, with the reduction attributed to the same reasons as the quarterly operating expenses drop.
Net loss for Q2 2025 $2.8 million or $0.36 per share compared to $3.8 million or $8.16 per share in Q2 2024, an improvement primarily due to the decrease in operating expenses.
Net loss for the 6 months ended June 30, 2025 $6.4 million compared to $7.4 million in the same period in 2024, with the improvement attributed to the same reasons as the quarterly net loss improvement.
Cash and cash equivalents as of June 30, 2025 $7.8 million compared to $6.5 million as of December 31, 2024, with no outstanding debt, providing flexibility to advance growth strategies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Catamaran SE: Second-generation low-profile implant on track for full commercial launch in the coming weeks. Favorable feedback and alpha review received.
Symmetry Plus system: Next-generation fusion platform designed to enhance SI joint portfolio. Initial alpha surgeries expected in Q4 2025.
SiVantage acquisition: Strategic acquisition completed, enhancing commercial organization, hospital approval processes, distribution networks, and market access. Expected to drive sustainable top-line growth.
Operating expenses: Reduced by 29% year-over-year, demonstrating tighter discipline while preserving growth investments.
Cash position: Ended Q2 2025 with $7.8 million in cash and no debt, providing flexibility for strategic initiatives.
Strategic shift in commercial initiatives: Shifted focus to integrate SiVantage acquisition, resulting in lower procedure volumes but expected to drive future growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for Q2 2025 decreased to $564,000 from $901,000 in the same period last year, and for the first half of 2025, revenue dropped to $1.3 million from $1.6 million in the same period of 2024. This decline was attributed to lower procedure volumes and account mix headwinds, primarily due to the strategic shift in commercial initiatives related to the SiVantage acquisition.
Gross Margin Decline: Gross profit margin fell to 43% in Q2 2025 from 52% in the prior year quarter, driven by reduced procedure volumes and lower revenue, while fixed production overhead costs remained consistent.
Net Loss: The company reported a net loss of $2.8 million in Q2 2025, an improvement from $3.8 million in Q2 2024, but still a significant financial challenge.
Integration Risks: The integration of the SiVantage acquisition, expected to take 60-90 days, poses risks related to operational disruptions, alignment of commercial infrastructure, and realization of anticipated synergies.
Market Competition: The sacropelvic marketplace is described as increasingly competitive, which could challenge Tenon's ability to differentiate its products and maintain market share.
Product Launch Risks: The upcoming launches of Catamaran SE and Symmetry Plus carry risks related to market adoption, physician acceptance, and operational execution.
Economic Uncertainty: Broader economic conditions and uncertainties could impact procedure volumes, hospital budgets, and overall demand for Tenon's products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SiVantage Integration: The integration of SiVantage is expected to take place over the next 60 to 90 days. This acquisition is anticipated to enhance commercial organization, unlock new pathways through hospital approval processes, distribution networks, and market access, and energize the commercial infrastructure to drive sustainable top-line growth.
Catamaran SE Launch: The Catamaran SE, a second-generation low-profile implant, is on track for a full commercial launch in the coming weeks. This platform has already received favorable feedback and is expected to differentiate Tenon in the competitive sacropelvic marketplace.
Symmetry Plus System: Initial alpha surgeries using the newly developed Symmetry Plus system are expected to begin in Q4 2025. This next-generation fusion platform is designed to enhance the SI joint portfolio with features for long-term fusion outcomes.
MAINSAIL Post-Market Study: The MAINSAIL post-market study remains on track for the publication of the second interim analysis this quarter. The study aims to provide clinical validation through primary endpoints such as VAS and ODI scores, patient satisfaction, and secondary endpoints like fusion assessed via CT scan.
Financial Flexibility: The company ended the quarter with $7.8 million in cash and no debt, providing flexibility to execute its strategic roadmap, including product launches and market access efforts.
Market Expansion and Growth: The company is entering a period of sustained momentum with key milestones such as the SiVantage integration, Catamaran SE launch, and MAINSAIL interim data publication, which are expected to expand the addressable market and drive top-line growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the purpose of the SiVantage acquisition/merger?
A:The purpose is to achieve scale, leverage cost, and enhance the business model. It provides a pathway to scale, access to hospital system contract groups, and diversified product offerings. It also brings experienced personnel to the team, enabling more effective commercialization.
Q:Can you provide details on the combined revenue, OpEx, and gross margin of the merged company?
A:Audited financials are being completed and will be filed within a 75-day post-close period, expected by mid-October. The merger provides immediate revenue pickup, particularly from the Symmetry product line and the upcoming Symmetry Plus launch in Q4.
Q:Is the merger final, or are there any remaining steps?
A:The merger is final and approved. The only remaining step is filing the audited 2024 financials and the review period for 2025 for SiVantage, which is in progress.
Q:How should we think about Catamaran revenues in Q3 and Q4?
A:Q2 revenues were impacted by the merger process, but recovery is expected in Q3. The combined rollout in Q4, including incremental revenue from Symmetry, is anticipated to boost revenues. Cross-selling and leveraging hospital agreements will also contribute to growth.
Q:What is the incremental physician and hospital network acquired through the SiVantage acquisition?
A:There is overlap and incremental access at the physician and hospital levels. Integration and cross-selling have already begun, with training underway to prepare sales teams to sell across the portfolio.
Q:What is the reimbursement landscape for the Symmetry and Symmetry Plus products?
A:The SI joint procedures are covered by three distinct CPT codes, which also apply to the SiVantage technology. Both Catamaran and SiVantage products are supported by data to ensure proper coverage. No new incremental codes are required.
Q:What details can you provide about the Symmetry Plus launch?
A:The Symmetry Plus launch is planned to begin alpha surgeries in October with physician advisers providing feedback. A full-scale launch is expected in early 2024, depending on the feedback and necessary adjustments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the combined revenue, OpEx, and gross margin of the merged company, citing the need to complete audited financials. They also used vague language regarding the timing and impact of the Symmetry Plus launch, as it depends on feedback and adjustments during the alpha phase.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AO principle
CEO President
Catamaran case
Catamaran role
Conference Instructions
Director Nicholas
Division Conference
Division Scott
Dr
GA RD
MAINSAIL
ODI
Research Division
SiVantage acquisition
Symmetry system
VAS
adoption
alpha
debt flexibility
decline
fixation
focus
footprint
fusion solution
integration
loss share
month period
procedure volume
product
reduction GA
score
step
track
transaction
validation
TNON Transcript
Tenon Medical, Inc. (TNON) Q1 2026 Earnings Call Transcript
Positive5-13
The company's strong Q1 performance, with a 90% revenue increase and significant gross margin improvement, is encouraging. Positive sentiments from management and analysts, along with upcoming product launches and a sustainable high gross margin, suggest a positive outlook. Despite risks like operating expenses and convertible note financing, the overall sentiment is positive, supported by optimistic guidance and strategic initiatives.
Central Asia Metals plc (CAMLF) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call highlighted several concerns: a significant impairment charge, increased costs, and negative EPS. Although revenue grew, it was offset by rising costs and a substantial impairment. The Q&A revealed vague responses on cost management and future projects, adding uncertainty. The reinstated dividend policy is a positive, but overall, the financial health and guidance raise concerns. Given these factors, the sentiment is negative, suggesting a potential stock price decline of -2% to -8% in the short term.
Tenon Medical, Inc. (TNON) Q4 2025 Earnings Call Transcript
Positive3-19
The company demonstrated strong financial performance with a significant increase in both quarterly and annual revenue, driven by new product adoption. Gross margins improved, and net losses decreased, indicating operational efficiency. Despite competitive pressures, the strategic expansion of the product portfolio and positive reception of new launches like SImmetry+ suggest potential growth. The Q&A revealed management's optimism about revenue growth, despite vague guidance. The decrease in cash reserves is a concern but offset by strategic investments. Overall, the positive financial results and optimistic outlook suggest a positive stock price movement.
Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
TNON Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
